- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Choueiri on the Efficacy of Post-Nephrectomy, Adjuvant Pembrolizumab in RCC
June 4th 2021, 9:30pm
Toni K. Choueiri, MD, discusses the efficacy of pembrolizumab as a post-nephrectomy adjuvant therapy for patients with renal cell carcinoma from the phase 3 KEYNOTE-564 trial.
Nivolumab/Ipilimumab Plus Chemotherapy Shows Durable Benefit in Advanced NSCLC
June 4th 2021, 8:40pm
Nivolumab and ipilimumab plus 2 cycles of platinum-based chemotherapy demonstrated durable survival benefit vs chemotherapy alone in patients with advanced non–small cell lung cancer.
CLN-081 Elicits Encouraging Efficacy and Safety in EGFR Exon 20–Positive NSCLC
June 4th 2021, 7:50pm
CLN-081 demonstrated promising preliminary antitumor activity and an acceptable safety profile across all doses tested in patients with previously treated non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
Tivozanib Doubles DOR Vs Sorafenib in mRCC
June 4th 2021, 7:43pm
Tivozanib led to a more than doubled median duration of response compared with sorafenib in patients with metastatic renal cell carcinoma.
Frontline Avelumab Maintenance Improves OS Regardless of Primary Tumor Site, Advanced Disease Type in Advanced Urothelial Cancer
June 4th 2021, 7:35pm
Avelumab as frontline maintenance plus best supportive care demonstrated a survival benefit compared with BSC alone across several previously unreported subgroups of patients with advanced urothelial cancer who have progressed on first-line platinum-containing chemotherapy.
Updated Findings Confirm Long-Term Survival Benefit with Durvalumab in NSCLC
June 4th 2021, 7:35pm
Data from an updated analysis of the phase 3 PACIFIC trial indicate that treatment with durvalumab after chemoradiotherapy is associated with long-term survival improvements in patients with unresectable stage III non-small cell lung cancer.
4-Year Findings Confirm Long-Term Benefit for Nivo/Ipi in First Line for mNSCLC
June 4th 2021, 6:15pm
The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.
Cirmtuzumab Plus Ibrutinib Had Overall Response Rates in MCL and CLL
June 4th 2021, 6:11pm
Cirmtuzumab and ibrutinib led to reported high overall response rates in patients with mantle cell lymphoma or chronic lymphocytic leukemia.
Antitumor Activity Demonstrated With Novel PSMA-Targeted Agent HPN424 in mCRPC
June 4th 2021, 6:04pm
The tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager HPN424 demonstrated antitumor activity and was well tolerated in patients with metastatic castration-resistant prostate cancer.
Mobocertinib Elicits Anticancer Activity in Platinum-Pretreated EGFR Exon 20 Insertion+ Advanced NSCLC
June 4th 2021, 5:50pm
Mobocertinib, a first-in-class, oral, EGFR TKI, induced rapid, deep, and durable responses and a manageable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.
Deep Responses Yielded by Cilta-Cel in Relapsed/Refractory Multiple Myeloma
June 4th 2021, 5:29pm
Deep and early responses were yielded with a single infusion of ciltacabtagene autoleucel in patients with previously treated, relapsed/refractory multiple myeloma.
Concurrent Pembrolizumab Plus Chemoradiation Therapy Elicits Antitumor Activity in NSCLC
June 4th 2021, 5:23pm
Pembrolizumab plus concurrent chemoradiation therapy induced antitumor effects in patients with unresectable, locally advanced, stage III non–small cell lung cancer irrespective of PD-L1 expression or tumor histology.
Brigatinib Maintains Long-Term Efficacy in Crizotinib-Refractory ALK+ NSCLC
June 4th 2021, 4:47pm
Brigatinib demonstrated sustained long-term responses and survival in patients with crizotinib-refractory ALK-positive non–small cell lung cancer.
Extended Treatment With Darolutamide Well Tolerated, Prolongs Survival in Nonmetastatic CRPC
June 4th 2021, 4:41pm
Darolutamide remained well tolerated with a highly favorable safety profile when combined with androgen deprivation therapy in the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Pralsetinib Is Tolerable, Durable in RET Fusion-Positive NSCLC
June 4th 2021, 4:40pm
Updated findings from the ARROW trial demonstrated that pralsetinib could benefit those with RET fusion–positive non–small cell lung cancer and is a well-tolerated agent in the patient population.
Higher Dose of Ripretinib Improves Outcomes in Heavily Pretreated Advanced GIST
June 4th 2021, 4:37pm
Intra-patient dose escalation of ripretinib to 150 mg twice a day following disease progression extended progression-free survival for patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy.
Ide-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma
June 4th 2021, 4:30pm
The CAR T-cell therapy idecabtagene vicleucel continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma.
PFS Improved With Niraparib Maintenance in BRCA+ Ovarian Cancer
June 4th 2021, 4:21pm
Maintenance therapy with niraparib significantly improved progression-free survival in patients with BRCA-mutated ovarian cancer, according to results from three phase 3 trials.
Lenvatinib Plus Pembrolizumab May Increase OS Rates in Advanced Colorectal Cancer
June 4th 2021, 3:44pm
Some patients with previously treated advanced colorectal cancer responded to treatment with lenvatinib plus pembrolizumab.
Frontline Nivolumab Plus Ipilimumab or Chemo Improves Survival Outcomes in Advanced ESCC
June 3rd 2021, 9:00pm
The addition of nivolumab to either ipilimumab or chemotherapy resulted in improved survival outcomes vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.